ICAM1 and cancer: TIMP-3 downregulation is related to cancer invasion and metastasis in various cancers; however, higher serum level of TIMP-1 is associated with lower response to therapy in breast cancer patients [107], and TIMP-1 has been used as a biomarker along with MMP-2 and ICAM-1 for pancreatic cancer [108,109].